Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis

• Published in: Journal of hepatocellular carcinoma Vol. 10; pp. 1129 - 1141
• Main Authors: Ozer, Muhammet, Goksu, Suleyman Yasin, Lin, Rick Y, Ayasun, Ruveyda, Kahramangil, Doga, Rogers, Sherise C, Fabregas, Jesus C, Ramnaraign, Brian H, George, Thomas J, Feely, Michael, Cabrera, Roniel, Duarte, Sergio, Zarrinpar, Ali, Sahin, Ilyas
• Format: Journal Article
• Language: English
• Published: New Zealand Dove 01-01-2023; Dove Medical Press
• Subjects: bone metastasis; hcc; hepatocellular carcinoma; Original Research; bone metastasis; HCC; hepatocellular carcinoma
• ISSN: 2253-5969; 2253-5969
• DOI: 10.2147/JHC.S417273

Advanced hepatocellular carcinoma (HCC) generally has a dismal prognosis. Bone metastases from HCC are infrequent, with a poorer prognosis. However, the survival influencing factors are not yet well understood.
The aim of the present study was to assess the clinical features and tumor characteristics of HCC patients with bone metastasis.
A cohort of 170,576 adult patients with HCC was studied using the National Cancer Database (NCDB) spanning from 2010 to 2019, and within this group, 5285 patients (3.1%) were diagnosed with bone metastasis. We performed the Kaplan-Meier method to calculate the median overall survival (OS). We included demographics (age at diagnosis, gender, race, insurance status), comorbidity score, and treatment characteristics.
Of a total of 5285 HCC patients with bone metastasis, 86.2% were male and 61.2% were non-Hispanic white. Most patients (55.1%) were below 65, and 89% had a total Charlson-Deyo comorbidity score of under 3. Among patients with known tumor grade, 24.8% had well-differentiated tumors, and 36.1% had poorly differentiated tumors. Chemotherapy was administrated to 39.5% of patients. In univariate analysis, patients with well-differentiated tumors had better OS compared to poorly differentiated tumors (5.4 months vs 3.0 months, p = 0.001). Patients who received single or multiagent chemotherapy were significantly associated with improved OS compared to patients who did not receive chemotherapy (7.0 and 8.5 months vs 1.94 months, respectively). We also found mortality difference between age, comorbidity scores, facility types and race groups.
In this cohort analysis of NCDB data, we found better OS in treatment receipt, lower tumor grade, younger age, non-Hispanic Black and Hispanic race, treatment at academic facility and lower comorbidity score in HCC patients with bone metastasis. The study results may have a consequential impact on the treatment decisions for HCC patients with bone metastasis.